Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 88 articles:
HTML format
Text format



Single Articles


    September 2017
  1. SHUKLA V, Rao M, Zhang H, Beers J, et al
    ASXL3 is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer.
    Cancer Res. 2017 Sep 21. pii: canres.0570.2017.
    PubMed     Text format     Abstract available


  2. YAO M, Yu T, Zhao YJ, Hu Z, et al
    MetaLnc9 facilitates lung cancer metastasis via a PGK1-activated AKT/mTOR pathway.
    Cancer Res. 2017 Sep 18. pii: canres.0671.2017.
    PubMed     Text format     Abstract available


  3. KACHLER K, Bailer M, Heim L, Schumacher F, et al
    Enhanced acid sphingomyelinase activity drives immune evasion and tumor growth in non-small cell lung carcinoma.
    Cancer Res. 2017 Sep 7. pii: canres.3313.2016.
    PubMed     Text format     Abstract available


    August 2017
  4. KASIRI S, Shao C, Chen B, Wilson AN, et al
    GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma.
    Cancer Res. 2017;77:4448-4459.
    PubMed     Text format     Abstract available


    July 2017
  5. DU W, Xu X, Niu Q, Zhang X, et al
    Spi-B-mediated silencing of Claudin-2 promotes early dissemination of lung cancer cells from primary tumors.
    Cancer Res. 2017 Jul 28. pii: canres.0020.2017.
    PubMed     Text format     Abstract available


  6. COOPER JM, Ou YH, McMillan E, Vaden RM, et al
    TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer.
    Cancer Res. 2017 Jul 17. pii: canres.0829.2017.
    PubMed     Text format     Abstract available


  7. JERMYN M, Mercier J, Aubertin K, Desroches J, et al
    Highly Accurate Detection of Cancer In Situ with Intraoperative, Label-Free, Multimodal Optical Spectroscopy.
    Cancer Res. 2017;77:3942-3950.
    PubMed     Text format     Abstract available


  8. JIANG H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, et al
    Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.
    Cancer Res. 2017;77:3894-3907.
    PubMed     Text format     Abstract available


  9. CHAKRABARTI S, Michor F
    Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution.
    Cancer Res. 2017;77:3908-3921.
    PubMed     Text format     Abstract available


    June 2017
  10. RICHER AL, Cala JM, O'Brien K, Carson VM, et al
    WEE1 kinase inhibitor AZD1775 has pre-clinical efficacy in LKB1-deficient non-small cell lung cancer.
    Cancer Res. 2017 Jun 26. pii: canres.3565.2016.
    PubMed     Text format     Abstract available


  11. TRIPATHI SC, Fahrmann JF, Celiktas M, Aguilar M, et al
    MCAM mediates chemoresistance in small cell lung cancer via the PI3K/AKT/SOX2 signaling pathway.
    Cancer Res. 2017 Jun 23. pii: canres.2874.2016.
    PubMed     Text format     Abstract available


    May 2017
  12. RIOS VELAZQUEZ E, Parmar C, Liu Y, Coroller TP, et al
    Somatic mutations drive distinct imaging phenotypes in lung cancer.
    Cancer Res. 2017 May 31. pii: canres.0122.2017.
    PubMed     Text format     Abstract available


  13. YE M, Zhang Y, Zhang X, Zhang JB, et al
    Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non-small cell lung cancer.
    Cancer Res. 2017 May 18. pii: canres.3470.2016.
    PubMed     Text format     Abstract available


  14. SEN T, Tong P, Stewart CA, Cristea S, et al
    CHK1 inhibition in small cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib.
    Cancer Res. 2017 May 10. pii: canres.3409.2016.
    PubMed     Text format     Abstract available


  15. PRAT A, Navarro A, Pare L, Reguart N, et al
    Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma and melanoma.
    Cancer Res. 2017 May 9. pii: canres.3556.2017.
    PubMed     Text format     Abstract available


  16. SHARMA SK, Pourat J, Abdel-Atti D, Carlin SD, et al
    Non-invasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
    Cancer Res. 2017 May 9. pii: canres.0299.2017.
    PubMed     Text format     Abstract available


  17. PAILLER E, Oulhen M, Borget I, Remon J, et al
    Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.
    Cancer Res. 2017;77:2222-2230.
    PubMed     Text format     Abstract available


    April 2017
  18. ICHIHARA E, Westover D, Meador CB, Yan Y, et al
    SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer.
    Cancer Res. 2017 Apr 17. pii: canres.2300.2016.
    PubMed     Text format     Abstract available


  19. ZHANG Y, Xu W, Guo H, Zhang Y, et al
    NOTCH1 Signaling Regulates Self-renewal and Platinum Chemoresistance of Cancer Stem-like Cells in Human Non-small Cell Lung Cancer.
    Cancer Res. 2017 Apr 17. pii: canres.1633.2016.
    PubMed     Text format     Abstract available


  20. STEVENS LE, Cheung WKC, Adua SJ, Arnal-Estape A, et al
    Extracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of Micrometastases.
    Cancer Res. 2017;77:1905-1917.
    PubMed     Text format     Abstract available


  21. WEN H, Chiu YF, Kuo MH, Lee KL, et al
    Expression of neuroendocrine factor VGF in lung cancer cells confers resistance to EGFR kinase inhibitors and triggers epithelial-to-mesenchymal transition.
    Cancer Res. 2017 Apr 5. pii: canres.3168.2016.
    PubMed     Text format     Abstract available


  22. WALTER DM, Venancio OS, Buza EL, Tobias JW, et al
    Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma.
    Cancer Res. 2017;77:1719-1729.
    PubMed     Text format     Abstract available


    March 2017
  23. LIAO L, Song M, Li X, Tang L, et al
    E3 ubiquitin ligase UBR5 drives the growth and metastasis of triple negative breast cancer.
    Cancer Res. 2017 Mar 22. pii: canres.2409.2016.
    PubMed     Text format     Abstract available


    February 2017
  24. WANG M, Han J, Marcar L, Black J, et al
    Radiation resistance in KRAS-mutated lung cancer is enabled by stem-like properties mediated by an osteopontin-EGFR pathway.
    Cancer Res. 2017 Feb 15. pii: canres.0808.2016.
    PubMed     Text format     Abstract available


  25. ZHANG Y, Wei Y, Jiang B, Chen L, et al
    Scavenger receptor A1 prevents metastasis of non-small cell lung cancer via suppression of macrophage serum amyloid A1.
    Cancer Res. 2017 Feb 15. pii: canres.1569.2016.
    PubMed     Text format     Abstract available


  26. KAREKLA E, Liao WJ, Sharp B, Pugh J, et al
    Ex vivo explant cultures of non-small cell lung carcinoma enable evaluation of primary tumor responses to anticancer therapy.
    Cancer Res. 2017 Feb 15. pii: canres.1121.2016.
    PubMed     Text format     Abstract available


  27. NUKAGA S, Yasuda H, Tsuchihara K, Hamamoto J, et al
    Amplification of EGFR wild type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors.
    Cancer Res. 2017 Feb 15. pii: canres.2359.2016.
    PubMed     Text format     Abstract available


    January 2017
  28. HAN SY, Ko A, Kitano H, Choi CH, et al
    Molecular Chaperone HSP90 Is Necessary to Prevent Cellular Senescence via Lysosomal Degradation of p14ARF.
    Cancer Res. 2017;77:343-354.
    PubMed     Text format     Abstract available


  29. KYUNG RHO J, Young Lee I, Jung Choi Y, Choi CM, et al
    Superior efficacy and selectivity of novel small molecule kinase inhibitors of T790M mutant EGFR in preclinical models of lung cancer.
    Cancer Res. 2017 Jan 12. pii: canres.2432.2016.
    PubMed     Text format     Abstract available


  30. KAUFMAN JM, Yamada T, Park K, Timmers CD, et al
    A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.
    Cancer Res. 2017;77:153-163.
    PubMed     Text format     Abstract available


  31. ZHOU X, Updegraff BL, Guo Y, Peyton M, et al
    PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis.
    Cancer Res. 2017;77:187-197.
    PubMed     Text format     Abstract available


  32. MAMAN S, Sagi-Assif O, Yuan W, Ginat R, et al
    The Beta Subunit of Hemoglobin (HBB2/HBB) Suppresses Neuroblastoma Growth and Metastasis.
    Cancer Res. 2017;77:14-26.
    PubMed     Text format     Abstract available


    December 2016
  33. TASSI E, Grazia G, Vegetti C, Bersani I, et al
    Early effector T lymphocytes coexpress multiple inhibitory receptors in primary non-small cell lung cancer.
    Cancer Res. 2016 Dec 15. pii: canres.1387.2016.
    PubMed     Text format     Abstract available


  34. UDYAVAR AR, Wooten DJ, Hoeksema MD, Bansal M, et al
    Novel hybrid phenotype revealed in Small Cell Lung Cancer by a transcription factor network model that can explain tumor heterogeneity.
    Cancer Res. 2016 Dec 8. pii: canres.1467.2016.
    PubMed     Text format     Abstract available


    November 2016
  35. DOWER CM, Bhat N, Wang EW, Wang HG, et al
    Selective Reversible Inhibition of Autophagy in Hypoxic Breast Cancer Cells Promotes Pulmonary Metastasis.
    Cancer Res. 2016 Nov 15. doi: 10.1158/0008-5472.CAN-15-3458.
    PubMed     Text format     Abstract available


  36. PAIDI SK, Rizwan A, Zheng C, Cheng M, et al
    Label-Free Raman Spectroscopy Detects Stromal Adaptations in Premetastatic Lungs Primed by Breast Cancer.
    Cancer Res. 2016 Nov 15. doi: 10.1158/0008-5472.CAN-16-1862.
    PubMed     Text format     Abstract available


    October 2016
  37. SCHELHAAS S, Held A, Wachsmuth L, Hermann S, et al
    Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3'-Deoxy-3'-[18F]Fluorothymidine in Preclinical Models of Lung Cancer.
    Cancer Res. 2016 Oct 26. pii: canres.1479.2016.
    PubMed     Text format     Abstract available


    September 2016
  38. UM SW, Joung JG, Lee H, Kim H, et al
    Molecular evolution patterns in metastatic lymph nodes reflect the differential treatment response of advanced primary lung cancer.
    Cancer Res. 2016 Sep 13. pii: canres.0873.2016.
    PubMed     Text format     Abstract available


    August 2016
  39. BAGHDADI M, Wada H, Nakanishi S, Abe H, et al
    Chemotherapy-induced IL-34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells.
    Cancer Res. 2016 Aug 22. pii: canres.1170.2016.
    PubMed     Text format     Abstract available


  40. YASUFUKU K, Jin CS, Wada H, Anayama T, et al
    An integrated nanotechnology-enabled transbronchial image-guided intervention strategy for peripheral lung cancer.
    Cancer Res. 2016 Aug 19. pii: canres.3196.2015.
    PubMed     Text format     Abstract available


  41. PATEL YM, Park SL, Han Y, Wilkens LR, et al
    Novel Association of Genetic Markers Affecting CYP2A6 activity and Lung Cancer Risk.
    Cancer Res. 2016 Aug 3. pii: canres.0446.2016.
    PubMed     Text format     Abstract available


  42. YOLDI G, Pellegrini P, Trinidad EM, Cordero A, et al
    RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation.
    Cancer Res. 2016 Aug 1. pii: canres.2745.2015.
    PubMed     Text format     Abstract available


    June 2016
  43. HALL Z, Ament Z, Wilson CH, Burkhart DL, et al
    Myc expression drives aberrant lipid metabolism in lung cancer.
    Cancer Res. 2016 Jun 22. pii: canres.3403.2015.
    PubMed     Text format     Abstract available


  44. OH AY, Jung YS, Kim J, Lee JH, et al
    Inhibiting DX2-p14/ARF interaction exerts antitumor effects in lung cancer and delays tumor progression.
    Cancer Res. 2016 Jun 14. pii: canres.1025.2015.
    PubMed     Text format     Abstract available


  45. CHALLA S, Guo J, Ding X, Xu CX, et al
    IKBKE is a substrate of EGFR and a therapeutic target in non-small cell lung cancer with activating mutations of EGFR.
    Cancer Res. 2016 Jun 10. pii: canres.0069.2016.
    PubMed     Text format     Abstract available


    May 2016
  46. MARWITZ S, Depner S, Dvornikov D, Merkle R, et al
    Downregulation of the TGF-beta pseudoreceptor BAMBI in non-small cell lung cancer enhances TGF-beta signaling and invasion.
    Cancer Res. 2016 May 17. pii: canres.1326.2015.
    PubMed     Text format     Abstract available


    April 2016
  47. CAETANO MS, Zhang H, Cumpian AM, Gong L, et al
    IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  48. BOUTET M, Gauthier L, Leclerc M, Gros G, et al
    TGFbeta Signaling Intersects with CD103 Integrin Signaling to Promote T-Lymphocyte Accumulation and Antitumor Activity in the Lung Tumor Microenvironment.
    Cancer Res. 2016;76:1757-69.
    PubMed     Text format     Abstract available


  49. FUCIKOVA J, Becht E, Iribarren K, Goc J, et al
    Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis.
    Cancer Res. 2016;76:1746-56.
    PubMed     Text format     Abstract available


    March 2016
  50. LIU Y, Amin EB, Mayo MW, Chudgar NP, et al
    CK2alpha' Drives Lung Cancer Metastasis by Targeting BRMS1 Nuclear Export and Degradation.
    Cancer Res. 2016 Mar 15. pii: canres.2888.2015.
    PubMed     Text format     Abstract available


  51. BOUILLEZ A, Rajabi H, Pitroda S, Jin C, et al
    Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.
    Cancer Res. 2016;76:1538-48.
    PubMed     Text format     Abstract available


  52. JOHNSON N, De Ieso P, Migliorini G, Orr N, et al
    Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  53. KOYAMA S, Akbay EA, Li YY, Aref AR, et al
    STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
    Cancer Res. 2016;76:999-1008.
    PubMed     Text format     Abstract available


  54. CHOI SH, Nam JK, Kim BY, Jang J, et al
    HSPB1 Inhibits the Endothelial-to-Mesenchymal Transition to Suppress Pulmonary Fibrosis and Lung Tumorigenesis.
    Cancer Res. 2016;76:1019-30.
    PubMed     Text format     Abstract available


    February 2016
  55. BROOKS GD, McLeod L, Alhayyani S, Miller A, et al
    IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis.
    Cancer Res. 2016;76:866-76.
    PubMed     Text format     Abstract available


  56. MURAYAMA T, Nakaoku T, Enari M, Nishimura T, et al
    Oncogenic Fusion Gene CD74-NRG1 Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  57. FUJITA H, Nagakawa K, Kobuchi H, Ogino T, et al
    Phytoestrogen suppresses efflux of the diagnostic marker protoporphyrin IX (PpIX) in lung carcinoma.
    Cancer Res. 2016 Feb 2. pii: canres.1484.2015.
    PubMed     Text format     Abstract available


  58. BRENTVILLE VA, Metheringham RL, Gunn B, Symonds P, et al
    Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell-Mediated Antitumor Immunity.
    Cancer Res. 2016;76:548-60.
    PubMed     Text format     Abstract available


  59. LI M, Kales SC, Ma K, Shoemaker BA, et al
    Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.
    Cancer Res. 2016;76:561-71.
    PubMed     Text format     Abstract available


    January 2016
  60. JIA Y, Juarez J, Li J, Manuia M, et al
    EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor.
    Cancer Res. 2016 Jan 29. pii: canres.2581.2015.
    PubMed     Text format     Abstract available


  61. YAN J, Ojo D, Kapoor A, Lin X, et al
    Neural cell adhesion protein CNTN1 promotes the metastatic progression of prostate cancer.
    Cancer Res. 2016 Jan 21. pii: canres.1898.2015.
    PubMed     Text format     Abstract available


  62. OHAR JA, Cheung M, Talarchek J, Howard SE, et al
    Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
    Cancer Res. 2016;76:206-15.
    PubMed     Text format     Abstract available


  63. DE RIENZO A, Archer MA, Yeap BY, Dao N, et al
    Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma.
    Cancer Res. 2016;76:319-28.
    PubMed     Text format     Abstract available


  64. MEIER C, Hardtstock P, Joost S, Alla V, et al
    p73 and IGF1R Regulate Emergence of Aggressive Cancer Stem-like Features via miR-885-5p Control.
    Cancer Res. 2016;76:197-205.
    PubMed     Text format     Abstract available


  65. DUBOIS F, Keller M, Calvayrac O, Soncin F, et al
    RASSF1A suppresses the invasion and metastatic potential of human non-small cell lung cancer cells by inhibiting YAP activation through the GEF-H1/RhoB pathway.
    Cancer Res. 2016 Jan 12. pii: canres.1008.2015.
    PubMed     Text format     Abstract available


  66. AMATO KR, Wang S, Tan L, Hastings AK, et al
    EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


    December 2015
  67. ISOZAKI H, Ichihara E, Takigawa N, Ohashi K, et al
    Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases.
    Cancer Res. 2015 Dec 30. pii: canres.1010.2015.
    PubMed     Text format     Abstract available


  68. RIQUELME E, Behrens C, Lin HY, Simon GR, et al
    Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations.
    Cancer Res. 2015 Dec 16. pii: canres.1141.2015.
    PubMed     Text format     Abstract available


  69. LASTWIKA KJ, Wilson W 3rd, Li QK, Norris J, et al
    Control of PD-L1 expression by oncogenic activation of the AKT/mTOR pathway in non-small cell lung cancer.
    Cancer Res. 2015 Dec 4. pii: canres.3362.2014.
    PubMed     Text format     Abstract available


    November 2015
  70. MOMCILOVIC M, McMickle R, Abt E, Seki A, et al
    Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.
    Cancer Res. 2015;75:4910-22.
    PubMed     Text format     Abstract available


  71. LANZARDO S, Conti L, Rooke R, Ruiu R, et al
    Immunotargeting of antigen xCT attenuates stem-like cell behavior and metastatic progression in breast cancer.
    Cancer Res. 2015 Nov 13. pii: canres.1208.2015.
    PubMed     Text format     Abstract available


  72. CHOI JW, Kim JK, Yang YJ, Kim P, et al
    Urokinase exerts antimetastatic effects by dissociating clusters of circulating tumor cells.
    Cancer Res. 2015;75:4474-82.
    PubMed     Text format     Abstract available


  73. ZHANG W, Gao Y, Li F, Tong X, et al
    YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin.
    Cancer Res. 2015;75:4450-7.
    PubMed     Text format     Abstract available


  74. ELKIN SR, Bendris N, Reis CR, Zhou Y, et al
    A systematic analysis reveals heterogeneous changes in the endocytic activities of cancer cells.
    Cancer Res. 2015;75:4640-50.
    PubMed     Text format     Abstract available


    October 2015
  75. HAM B, Wang N, D'Costa Z, Fernandez MC, et al
    TNF receptor-2 facilitates an immunosuppressive microenvironment in the liver to promote the colonization and growth of hepatic metastases.
    Cancer Res. 2015 Oct 19. pii: canres.3173.2014.
    PubMed     Text format     Abstract available


  76. SOUCHERAY M, Capelletti M, Pulido I, Kuang Y, et al
    Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
    Cancer Res. 2015;75:4372-83.
    PubMed     Text format     Abstract available


  77. YAMADA T, Amann JM, Fukuda K, Takeuchi S, et al
    Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma.
    Cancer Res. 2015;75:4188-97.
    PubMed     Text format     Abstract available


    September 2015
  78. JACOB LS, Vanharanta S, Obenauf AC, Pirun M, et al
    Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations.
    Cancer Res. 2015;75:3713-9.
    PubMed     Text format     Abstract available


  79. VANGAMUDI B, Paul TA, Shah PK, Kost-Alimova M, et al
    The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
    Cancer Res. 2015;75:3865-78.
    PubMed     Text format     Abstract available


  80. GUO G, Gong K, Wohlfeld B, Hatanpaa KJ, et al
    Ligand-Independent EGFR Signaling.
    Cancer Res. 2015;75:3436-41.
    PubMed     Text format     Abstract available


    August 2015
  81. ZHANG Q, Qin J, Zhong L, Gong L, et al
    CCL5-mediated Th2 immune polarization promotes metastasis in luminal breast cancer.
    Cancer Res. 2015 Aug 6. pii: canres.3590.2014.
    PubMed     Text format     Abstract available


    June 2015
  82. KAPOOR V, Khudanyan A, de la Puente P, Campian J, et al
    Stem cell transfusion restores immune function in radiation-induced lymphopenic C57/BL6 mice.
    Cancer Res. 2015 Jun 30. pii: canres.1412.2015.
    PubMed     Text format     Abstract available


  83. CHANG YW, Su YJ, Hsiao M, Wei KC, et al
    Diverse Targets of beta-catenin during the Epithelial-Mesenchymal Transition Define Cancer Stem Cells and Predict Disease Relapse.
    Cancer Res. 2015 Jun 29. pii: canres.3265.2014.
    PubMed     Text format     Abstract available


    April 2015
  84. BONASTRE E, Verdura S, Zondervan I, Facchinetti F, et al
    PARD3 Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion.
    Cancer Res. 2015;75:1287-97.
    PubMed     Text format     Abstract available


  85. RICE WL, Shcherbakova DM, Verkhusha VV, Kumar AT, et al
    In vivo tomographic imaging of deep-seated cancer using fluorescence lifetime contrast.
    Cancer Res. 2015;75:1236-43.
    PubMed     Text format     Abstract available


    February 2015
  86. JIANG F, Chen L, Yang YC, Wang XM, et al
    CYP3A5 Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Regulating mTORC2/Akt Signaling.
    Cancer Res. 2015 Feb 3. pii: canres.1589.2014.
    PubMed     Text format     Abstract available


    January 2015
  87. YU J, Wang Y, Liu C, Luo M, et al
    Chemotherapy-induced miRNA-29c/catenin-delta signaling suppresses metastasis in gastric cancer.
    Cancer Res. 2015 Jan 29. pii: canres.0787.2014.
    PubMed     Text format     Abstract available


  88. NESKEY DM, Osman AA, Ow TJ, Katsonis P, et al
    Evolutionary Action score of TP53 (EAp53) identifies high risk mutations associated with decreased survival and increased distant metastases in head and neck cancer.
    Cancer Res. 2015 Jan 29. pii: canres.2735.2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: